0000950170-24-002278.txt : 20240104 0000950170-24-002278.hdr.sgml : 20240104 20240104214738 ACCESSION NUMBER: 0000950170-24-002278 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240102 FILED AS OF DATE: 20240104 DATE AS OF CHANGE: 20240104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McNeill Jonathan CENTRAL INDEX KEY: 0001824673 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39509 FILM NUMBER: 24514342 MAIL ADDRESS: STREET 1: C/O DYNE THERAPEUTICS, INC. STREET 2: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dyne Therapeutics, Inc. CENTRAL INDEX KEY: 0001818794 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364883909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 786-8230 MAIL ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 4 1 ownership.xml 4 X0508 4 2024-01-02 0001818794 Dyne Therapeutics, Inc. DYN 0001824673 McNeill Jonathan 1560 TRAPELO ROAD WALTHAM MA 02451 false true false false Chief Business Officer true Common Stock 2024-01-02 4 S false 11900 13.10 D 143618 D Common Stock 2024-01-03 4 M false 17991 0.73 A 161609 D Common Stock 2024-01-03 4 S false 7691 18.34 D 153918 D Common Stock 2024-01-03 4 S false 10300 19.03 D 143618 D Common Stock 2024-01-04 4 M false 2009 0.73 A 145627 D Common Stock 2024-01-04 4 S false 2009 18.04 D 143618 D Stock option (right to buy) 0.73 2024-01-03 4 M false 17991 0 D 2029-02-25 Common Stock 17991 50537 D Stock option (right to buy) 0.73 2024-01-04 4 M false 2009 0 D 2029-02-25 Common Stock 2009 48528 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.76 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. Includes 143,067 unvested RSUs. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.50, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $19.00 to $19.25, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.07, inclusive. The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter. /s/ Richard Scalzo, Attorney-in-Fact 2024-01-04